Table 1.

Baseline and clinical characteristics of patients (n = 87).

Age	71.34 ± 15.9
Female sex (vs male)	40 (46%)
BMI (kg/m2)	27.49 ± 4.43
Time from symptom onset to hospital admission (days)	6.78 ± 4.35
Time from symptom onset to ultrasound performance (days)	24.65 ± 13.01
Time from admission to ultrasound performance (days)	19.28 ± 11.39
Charlson index	4.43 ± 3.01
Smoking (pack years)
<5	61 (70.1%)
≥5	26 (29.9%)
Comorbidities
Hypertension	53 (60.9%)
Diabetes	29 (33.3%)
Dementia	27 (31%)
Structural cardiac disease	24 (27.6%)
Chronic obstructive lung disease/asthma	20 (23%)
Stroke	10 (11.5%)
Chronic kidney disease (eGFR < 30 ml/min)	7 (8%)
Coronary heart disease	6 (6.9%)
Previous antiplatelet therapy	22 (25.3%)
Previous anticoagulant therapy	15 (17.2%)
Predisposing factors for VT
History of VTE (either DVT, PE, or both)	2 (2.3%)
Immobilization	69 (79.3%)
Central vein catheterisation	24 (27.6%)
Other common risks factors for VT	13 (14.9%)
ICU admission	26 (29.9%)
Length of stay in ICU (days)	24.93 ± 13.08
Mechanical invasive ventilation	23 (26.4%)
Clinical severity score
Mild	7 (8%)
Moderate	26 (29.9%)
Severe	27 (31%)
Critical	27 (31%)
Treatment with anti-inflammatory drugs (during hospitalization)
None	37 (42.5%)
Steroids	48 (55.2%)
Tocilizumab	22 (25.3%)
Anakinra	3 (3.4%)
D-dimer (peak), mg/L (IQR)	10.02 ± 12.2 (1.4–12.9)
D-dimer at time of CTPA performance (mg/L)	8.01 ± 10.72

BMI = body mass index; eGFR = estimated glomerular filtration rate; NOAC = novel oral anticoagulants; VT = venous thrombosis; VTE = venous thromboembolism; PE = pulmonary embolism; DVT = deep venous thrombosis; ICU = intensive care unit; LMWH = low-molecular-weight heparin; IQR = interquartile range; CTPA = computed tomography pulmonary angiogram.

Quantitative variables are expressed in mean ± standard deviation, except those related to time, which are expressed in median.